Purdue Frederick
As of the edition of 20 October 2026, Purdue Frederick runs 8 drugs, 8 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Total | 8 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Morphine | none listed | 2 |
| Warfarin | none listed | 1 |
| Povidone-iodine | none listed | 0 |
| Malathion | Ends 2027 (patent) | 0 |
| Phenyl aminosalicylate | none listed | 0 |
| Quinidine polygalacturonate | none listed | 0 |
| Sulfaphenazole | none listed | 0 |
| Trolamine polypeptide oleate condensate | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Immune system: 1 trials led
- Infections: 1 trials led
- Urinary and reproductive: 1 trials led